Aims: To investigate the efficacy and safety of insulin degludec/liraglutide (IDegLira) compared with 50 U insulin degludec (degludec) or less in Japanese individuals with type 2 diabetes (T2D).
| INTRODUCTION
The prevalence of diabetes in the Japanese adult population is projected to increase from 7.7% in 2017 to 8.3% in 2045, 1 with the majority of cases being type 2 diabetes (T2D). [2] [3] [4] This increase in prevalence is attributed, in part, to changes in lifestyle such as diet and exercise. 5 Many patients with T2D will require insulin therapy because of the progressive nature of the disease. 6 Basal or pre-mix insulin, in combination with oral agents such as metformin, are established treatments for T2D in Japan. 7 However, many patients fail to achieve adequate glycaemic control and, therefore, may be at higher risk of developing long-term complications, 8 possibly as a result of clinical inertia. 9 Barriers to optimal initiation and titration of insulin can include the increased risk of hypoglycaemia and weight gain, as well as the burden of the number of injections necessary to titrate and administer complex insulin regimens that is experienced by patients. 10 To help overcome some of these barriers, combination therapy with basal insulin and a glucagon-like peptide-1 receptor agonist (GLP-1RA), administered as separate injections, has been recommended by the Japanese Diabetes Society following successful outcomes from recent global trials. 7 Basal insulin and GLP-1RAs, together, lower fasting plasma glucose (FPG) levels and reduce post-prandial glucose excursions, while limiting the risk of hypoglycaemia. 11 These effects may be particularly important in the ageing Japanese population. 12 Insulin degludec/liraglutide (IDegLira) is a fixed-ratio combination of insulin degludec (degludec) and the GLP-1RA liraglutide, administered as a once-daily single injection. 13, 14 The safety and efficacy of IDegLira has been investigated in a number of patient populations in the global DUAL clinical trial programme, including the global DUAL II study which confirmed the superiority of IDegLira over degludec alone in terms of glycaemic control and established the contribution of the liraglutide component in IDegLira in non-Japanese patients. 15 These trials led to the European approval of IDegLira in 2014 and to US approval in 2016. The aim of this study was to compare the efficacy and safety of IDegLira with that of degludec (≤50 units) in Japanese patients with T2D who were inadequately controlled with a basal or pre-mixed insulin regimen.
| RESEARCH DESIGN AND METHODS
This was a 26-week, multicentre, randomized, parallel, two-arm, treatto-target, double-blind trial (ClinicalTrials.gov NCT02911948) to investigate the efficacy and safety of IDegLira as compared to degludec, both in combination with metformin ( Figure 1 ). Degludec was capped at the same maximum dose (50 U) across treatment groups to allow for assessment of the contribution of the liraglutide component of IDegLira.
The trial comprised a 2-week screening period and a 26-week treatment period. Participants were Japanese adults with a body mass index (BMI) of at least 23 kg/m 2 and HbA1c levels between 58 and 97 mmol/Mol (7.5%-11.0%), who had been diagnosed with T2D at least 6 months prior to screening, and who had been undergoing stable therapy with basal or pre-mix/combination insulin (20-50 U) in combination with metformin for at least 60 days prior to screening. In addition to metformin, participants could also be receiving one of the following oral anti-diabetic drugs (OADs): sulphonylureas (SU), glinides, α-glucosidase inhibitors (α-GI), sodium-glucose cotransporter-2 inhibitors (SGLT2i) or thiazolidinediones (TZD).
The study protocol was approved by independent ethics committees or institutional review boards at all participating institutions. The study was performed in accordance with the Declaration of Helsinki and ICH Good Clinical Practice guidelines. Written consent was obtained from all participants before enrolment.
| Treatment
IDegLira and degludec were administered once daily at approximately the same time each day in a double-blind manner. The recommended starting doses were 10 dose steps of IDegLira (10 U degludec/0.36 mg liraglutide) or 10 U of degludec, with the option of a higher starting dose, up to 16 dose steps of IDegLira or 16 U of degludec, at the investigator's discretion depending on the condition of the patient. Both treatments were titrated twice weekly based on the mean of three consecutive pre-breakfast self-measured blood glucose (SMBG) values (Table S1 ). SMBG was assessed using a glucose meter calibrated to plasma equivalent values. The maximum dose was 50 dose steps (50 U degludec/1.8 mg liraglutide). All anti-diabetic treatments, with the exception of metformin, were discontinued at randomization. Metformin was continued at the pre-trial dose; however, in the case of safety concerns and at the investigator's discretion, the metformin dose could be reduced.
| Stratification and randomization
Participants were randomized 1:1, via a central interactive voice/web system, to receive either IDegLira or degludec, in combination with metformin. Particiants were stratified into four groups based on pretrial anti-diabetic treatment regimen: metformin plus basal insulin; metformin plus basal insulin and one other OAD; metformin plus premix/combination insulin; or metformin plus pre-mix/combination insulin and one other OAD. 
| Endpoints

| Statistical analysis
The primary objective was to confirm the superiority of IDegLira as compared to degludec in terms of change from baseline in HbA1c after 26 weeks of treatment. The sample size was determined using a t-statistic with α = 0.05 (two-sided test), a mean difference between treatments in change from baseline in HbA1c of −0.45% for IDegLira vs degludec for those who completed the study, a retained effect of 0.2% for withdrawals (assumed to be 15%) and a standard deviation of 1.0%. The above assumptions are based on experience from the global DUAL phase 3 development programme for IDegLira. From these assumptions, and based on 1:1 randomization, the sample size was determined to be 105 participants per treatment arm, a randomised population of at least 210 participants, which ensured a nominal power of at least 84.5%.
Continuous efficacy endpoints, including the primary endpoint, were analysed separately using an analysis of covariance (ANCOVA) model that included treatment and pre-trial anti-diabetic treatment as fixed effects and the baseline value of the parameter as a covariate. In the primary analysis of the primary endpoint, superiority was confirmed if the 95% CI for the treatment difference was entirely below 0.0%. Insulin dose was analysed using an ANCOVA model including 3 | RESULTS
| Participants
Of 267 patients screened, 210 were randomized (105 to each treatment group). No participants in the IDegLira group withdrew from treatment, compared with seven participants (6.7%) in the degludec group who withdrew. Subject disposition and reasons for withdrawal are given in Figure S1 . Baseline characteristics were similar between treatment groups and were representative of a T2D population that was inadequately controlled with their current treatment; treatment regimens at screening were comparable (Table 1 and Table S2 ). 
| Primary endpoint
| Insulin dose
After 26 weeks, the mean daily total insulin dose was significantly lower with IDegLira than with degludec (37.6 U vs 41.2 U, respectively) with an ETD of −3.08 U [−6.08; −0.08] 95%CI ; P = 0.0444 ( Figure 2(D) ). At end of trial, 34 (32.4%) participants in the IDegLira group were receiving the maximum dose of 50 dose steps and 49 (46.7%) participants in the degludec group were receiving the maximum dose of 50 U.
| HbA1c responders
The odds of achieving HbA1c targets and composite endpoints at the end of the trial were significantly higher for participants who received IDegLira compared with those who received degludec (P < 0.0001 in all cases) ( Figure 3 ). Of the participants receiving the maximum dose of IDegLira/degludec, 50%/18.4% achieved HbA1c less than 53 mmol/Mol (<7%), respectively.
| Nine-point SMBG profile
With the exception of the pre-breakfast period, SMBG values were significantly lower with IDegLira compared with degludec; P values ranged from less than 0.0001 to 0.024. After 26 weeks, mean nine-point (P = 0.0003). The mean prandial glucose increment at baseline and at
Week 26, and statistical analyses of change from baseline in prandial glucose increments, are presented in Table S3 .
| Blood pressure
Change in systolic and diastolic blood pressure was similar in the IDegLira and degludec groups, with ETDs of −0.57 mmHg [−4.17;
3.04] 95% CI ; P = 0.7575 and 0.89 mmHg [−1.37; 3.14] 95% CI ; P = 0.4381, respectively (Table S4 ). 
T A B L E 1 Baseline characteristics of participants
| Safety
| Adverse events
A summary of adverse events (AE) is given in . Elevated lipase levels were reported for two participants, both in the IDegLira arm. These events were non-serious, mild or moderate in severity, and were assessed by the investigator as possibly related to trial product. There were no reported AEs of increased amylase or calcitonin levels (≥20 ng/L). In the degludec treatment group there was one event of pancreatic carcinoma, which led to permanent discontinuation of trial product after 2 weeks of treatment; this event was considered by the investigator to be unrelated to degludec. Eight (7.6%) participants experienced an AE, which resulted in a dose reduction of IDegLira, at the investigator's discretion, whereas there were no dose reductions of degludec because of AEs.
| Serious adverse events
Three participants (2.9%) reported a total of four serious adverse events (SAEs) with IDegLira compared with four participants (3.8%) who reported a total of six SAEs with degludec. In the IDegLira group, one SAE (acute myocardial infarction) was confirmed by the Event Adjudication Committee (EAC) to be a major adverse cardiovascular event; however, this did not lead to changes in dosing. The EAC also confirmed two neoplasms (colorectal) in the IDegLira group, which were non-serious, of moderate severity and unlikely to be related to trial product. All four SAEs reported in the IDegLira group were considered unlikely to be related to treatment. In the degludec group, there was one EAC-confirmed neoplasm (pancreatic carcinoma), which was considered serious, of mild severity and unlikely to be related to trial product. Three of the SAEs reported in the degludec group were considered to be possibly related to treatment; these included two events of loss of consciousness, both related to excessive alcohol consumption, in the same participant and one event of acute cholecystitis. There were no deaths and no events of pancreatitis reported in this trial.
| Hypoglycaemia
The cumulative events of severe or BG-confirmed symptomatic hypoglycaemia are described in Figure S4 . The additional weight loss seen in the IDegLira group is attributed to the weight-lowering effect of liraglutide, which has been described in previous trials, 23 As per the protocol, the recommended starting dose was 10 dose steps/U of IDegLira/degludec, with the option of choosing a higher dose of up to 16 dose steps/U, at the investigator's discretion depending on the condition of the patient, for example, the risk of hyperglycaemia or hypoglycaemia. Pre-trial insulin products could be administered in up to 50 units/day; therefore, a potential concern might be that this considerable decrease in dose could cause uncontrolled glycaemia. However, in the IDegLira group, FPG levels began to decrease from baseline after the first week of treatment, confirming the safety of switching to IDegLira from a higher dose of pretrial insulin. Furthermore, although some participants received a starting dose above 10 dose steps, this did not lead to a high rate of gastrointestinal AEs and no participants in the IDegLira group withdrew. This is consistent with results of other clinical trials, which reported no loss of glycaemic control and no safety concerns when switching to a starting dose of 16 U of IDegLira from any pre-trial insulin dose between 20 and 50 U. 17, 24, 25 Overall, there were no unexpected safety or tolerability issues identified with treatment with IDegLira. The AE profile of IDegLira was consistent with that of liraglutide or degludec alone. This includes the higher incidence of gastrointestinal AEs such as diarrhoea, vomiting and nausea that was observed in the IDegLira group, which is expected according to the safety profile of liraglutide. The majority (four of seven) of gastrointestinal AEs leading to dose reduction occurred in the early period of the study, within 10 days of treatment randomization.
An increase in resting pulse was also observed with treatment with IDegLira, which is consistent with previous trials of IDegLira. 18 The clinical significance of this elevation is unknown but appears to be a class effect of long-acting GLP-1RAs. 26 Of note, cardiovascular benefits as compared to placebo have been reported for GLP-1RAs, including liraglutide. 27, 28 As with all randomized clinical trials, the findings of this trial may not be applicable to clinical practice or to patients who do not fit the specified inclusion and exclusion criteria. It is unclear if patients switching from more than 50 U of basal or pre-mix insulin to IDegLira would experience the same outcomes. In addition, it was necessary to cap the maximum dose of degludec at 50 U, to assess the contribution of the liraglutide component. Consequently, we cannot come to firm conclusions concerning the glucose-lowering or other effects of degludec, as a sub-group of participants in this trial may have required more than 50 U of insulin. However, in a previous trial comparing IDegLira to liraglutide and degludec, IDegLira had superior efficacy over degludec, despite no maximum dose. 29 Results from this trial confirm the safety and superior control over
HbA1c of IDegLira as compared to degludec in Japanese patients with T2D treated with basal or pre-mix insulin plus metformin, and one other OAD if required. In conclusion, IDegLira resulted in superior reductions in HbA1c as compared with up to 50 U degludec, with weight loss and similar rates of hypoglycaemia, and no unexpected safety or tolerability issues. Additionally, post-prandial increases were better controlled with IDegLira compared with degludec. These results suggest that this treatment could be an attractive intensification option for Japanese individuals with T2D that is uncontrolled with basal or pre-mixed insulin.
